Özet:

Purpose: In this study, we aimed to share the effectiveness and reliability of the autological hematopoietic root cell therapy (OHKHT) we apply in high-risk pediatric solid tumor patients with our 12 years of experience. Patients and Method: Data of pediatric malignity patients under the age of 18 in the Children's Bone Transplant Unit between January 2009 and July 2021 were evaluated retrospective. Results: 51 patients with an average age of 7.8 (0.5-18) years (24 girls, 27 men) were included in the study: there were 20, 15, 8, 4, 2 and 2 patients with neuroblastoma, ewing sarcoma, Hodgkin lymphoma, non-hodgkin lymphoma, germ cell tumor and soft tissue sarcoma, respectively. The patient's neutrophil and thrombocytes' median periods were 11 (8-45) days respectively and 16 (4-62) days and the median stay in the hospital was 38 (17-67) days. In all patients, the average follow-up period was 2.83 (0.12-10.81) years and the overall survival rate was 51.3±10.3 percent; the average follow-up period and survival rates of Ewing sarcoma and neuroblastoma occurrences were 2.63 (0.12-10,55) years respectively and 64.2 % ±14,9 and 2.81 (0.31-7.91) years and 42.8 % ±12. In neuroblastoma patients; all of the 4 patients receiving the preparation regime of carboplatin, etoposide, melfalan (CEM) died, while 6 of the 16 patients receiving the preparation regime of busulfan and melfalan (This/Mel) died: the average tracking time of this/Mel group was 3.08 (0.32-7.91) years and the overall survival was 55.1±13.8 % (p:0,001). The result: Although our number of patients is limited, it appears that in our clinic, in the data obtained in our cases of Ewing sarcoma and neuroblastoma, and in literature, OHKHT provides better survival than in patients not performed.